Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis

2 Sept 2024

Abstract excerpt

BACKGROUND: Acute myeloid leukemia (AML) is characterized by the abnormal proliferation of myeloid precursor cells and presents significant challenges in treatment due to its heterogeneity. Recently, the NLRP3 inflammasome has emerged as a potential contributor to AML pathogenesis, although its precise mechanisms remain poorly understood. METHODS: Public genome datasets were utilized to evaluate the expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Inflammasome and immune disorders
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39223663
DOI: 10.1186/s12964-024-01777-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosisPMID 39223663Read ↗

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemiaSemantic proximity Read ↗

The NLRP3 Inflammasome and Its Role in the Pathogenicity of LeukemiaSemantic proximity Read ↗

Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.Semantic proximity Read ↗

Autophagy and inflammasome molecular interplay and activation predict poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemiaSemantic proximity Read ↗

Analysis of prognostic biomarker models of TXNIP/NLRP3/IL1B inflammasome pathway in patients with acute myeloid leukemiaSemantic proximity Read ↗

Differential role of the NLRP 3 inflammasome in infection and tumorigenesisSemantic proximity Read ↗

Inflammasomes—New Contributors to Blood DiseasesSemantic proximity Read ↗

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapySemantic proximity Read ↗

Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.Semantic proximity Read ↗

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BSemantic proximity Read ↗

Multi-omics integration reveals immune hallmarks and biomarkers associated with FLT3 inhibitor sensitivity in FLT3-mutated AMLSemantic proximity Read ↗

Role of inflammasomes in cancer immunity: mechanisms and therapeutic potentialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.